CVLP

The NHS Cancer Vaccine Launchpad (CVLP) is a project to establish the feasibility of pathways to enable NHS patients with cancer to access cancer vaccine trials. We are investigating the optimum process for patients, across multiple cancer types, to receive personalised cancer vaccines by enrolment in the CVLP. The CVLP will facilitate the most comprehensive evaluation of this new form of cancer therapy.

The CVLP will support delivery of key UK ambitions, including Genome UK, The Life Sciences Vision, the NHS Genomics Strategy, and the NHS Long Term Plan. It includes these shared ambitions:

- That from 2028, 55,000 more people each year will survive their cancer for at least five years after diagnosis.

- To give patients an opportunity to participate in research for their potential benefit and to inform future care for other patients. - To accelerate the development of cancer vaccines from being an innovation to representing 'business-as-usual'.

- To create the most advanced and integrated genomic research healthcare ecosystem in the world.

- To use genomic research assets to drive the next generation of Life Sciences discoveries.

The CVLP team is a collaborative project including NHSE, Genomics England, the Department of Health and Social Care, the Office for Life Sciences, and the National Institute for Health and Care Research. We plan to enrol the first patient in 2023, and to scale up enrolment for thousands of patients across England to facilitate early access to cancer vaccines by 2030. 

1. Diagnosis (known or to felt to be highly likely) of primary or metastatic cancer among a range of cancer types

including but not limited to:

- colorectal carcinoma

- pancreatic cancer

- melanoma

- carcinoma of the lung

- prostate cancer

As the CVLP expands other tumour types are likely to be included.

2. Undergoing tumour resection or biopsy with sufficient tumour available for genomic analysis. Tumour samples

may be from resection or biopsy, from primary tumour or metastatic sites and from first presentation or at the time of

recurrence.

2. Over the age of 18

3. Capable of giving informed consent 

1. 1. Under the age of 18

2. 2. Incapable of giving informed consent 

Lead Research Nurse: Sarah Keith (sarah.keith@elht.nhs.uk)

Administrator: Oncology Research Team